Small cell lung cancer (SCLC) is a disease in which long-term survivors are few, the majority of patients dying within 2 years of diagnosis. Nevertheless, the identification of factors that predict likely survival, especially in the short-term, is of clinical importance since the treatment administered to a patient may depend on the prediction.
A number of studies of SCLC treatments have been carried out in the United Kingdom (Allan et al., 1984; Cullen et al., 1986 ; MRC Lung Cancer Working Party, 1979 Party, , 1981 Party, , 1983 Party, , 1989a Smyth et al., 1986; Souhami et al., 1984; Thatcher et al., 1982 Thatcher et al., , 1985a Thatcher et al., , b, 1987 . In some of these, analyses to determine important prognostic factors were also performed MRC Lung Cancer Working Party, 1981 , 1983 , 1989a Souhami et al., 1985; Vincent et al., 1987) . Several variables were demonstrated to be of importance in prognosis; these included performance status, disease stage, serum alkaline phosphatase (AlkP), plasma sodium (Na), serum albumin, serum lactate dehydrogenase (LDH), serum alanine aminotransferase (ALT), blood bicarbonate and age. However, the variables recorded and the methods of analysis differed between the studies, and the results were not entirely consistent.
Patients and methods
Information on a total of 3,873 SCLC patients was received from six centres as follows.
1. Results of four sequential studies, comprising a total of 434 patients treated in two hospitals, were received from the CRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester (Thatcher et al., 1982 (Thatcher et al., , 1985a (Thatcher et al., , b, 1987 . Since it had been shown previously that outcome was unrelated to treatment in these studies, the results were included as one data set. Up to 61 variables were recorded for each patient. LDH, disease stage, Na, Karnofsky performance status, AlkP and bicarbonate were reported to be the main prognostic factors .
2. Data from three non-randomised studies, comprising a total of 297 patients, were received from the ICRF Medical Oncology Unit, Western General Hospital, Edinburgh (Allan et al., 1984; Smyth et al., 1986) . There were no differences in outcome between the three treatment regimes and, therefore, the 297 patients were treated as one data set.
3. Data were received for 282 patients referred to the Lung Unit at the Royal Marsden Hospital (RMH), Sutton, Surrey, between 1978 and 1985 . The patients were treated according to a series of different chemotherapy protocols which ran consecutively during this period, but outcome was not related to any of the various treatments. Vincent et al. (1987) have previously performed a prognostic factor analysis on these data. They had 22 variables available for analysis, but deliberately omitted disease stage from their multivariate analysis. The evaluation of disease stage is often based on time-consuming and elaborate investigations and the aim of these authors was to devise a simple prognostic index excluding this variable. The (Souhami et al., 1984 (Souhami et al., 1985) . In the second trial, patients who died within three weeks of starting treatment were more likely to have a poor performance status, raised AlkP, raised blood urea and low albumin levels (Morittu et al., 1989 Party, 1979 Party, , 1981 Party, , 1983 Party, , 1989a , while the fourth is on-going and the data received comprised those patients entered in the trial by early 1988.
The variables that were available in two or more data sets are shown in Table I . The MRC data included only age, sex and disease stage for all four of its trials, and an activity status score, haemoglobin (Hb), white blood cell (WBC) and platelet counts in three of the four (Table I) (Karnofsky & Burchenal, 1949) was used, while in the other four either the Eastern Cooperative Oncology Group (ECOG) scale (Zubrod et al., 1960) (Cox, 1972 (Lee, 1980) . A significance level of 5% was set as the limit for From a preliminary analysis, it was clear that most variables were more strongly predictive of survival over the first 6 months than over the subsequent 18 months. Therefore, all analyses were divided into two components: an analysis of deaths occurring during the first 6 months after starting treatment (censoring those who were alive at the end of this time period) and a further analysis including only those patients who were alive at the end of the 6 month period.
After each analysis to identify the significant prognostic factors, the relevant subset was re-assessed to determine whether a 'similar' level of discrimination could be obtained with a smaller number of variables. There is no standard technique for this procedure and, therefore, an empirical method was adopted. The Cox scores were calculated from the full model, i.e. that consisting of all the significant prognostic factors, and these scores were used to divide the patients into three equal-sized groups with 'better', 'medium' or 'worse' prognosis. In the analyses of the initial 6 month period, the degree of discrimination between the three prognosis groups was assessed by calculating the 6 month survival rate in each group. The model was then reduced by excluding the factor that was the last to be entered by the forward stepwise procedure and the Cox scores for this model were calculated. The scores were again used to divide the patients into three equal-sized groups and the degree of discrimination re-examined. If the three 6 months survival rates were all within ± 2.5% of the respective survival rates obtained in the full model, the degree of discrimination was considered to be 'similar' and, thus, to be acceptable. This process was repeated until one or more of the rates were outside this limit. The 'reduced' model was taken to be the one with the minimum number of variables for which the survival rates were all within ± 2.5% of those obtained using the full model. The same procedure was used to analyse the 2 year survival rates of patients who survived at least 6 months. (Table  V) . Table IV 'similar' to that of the original full model. In each of analyses G-I only a relatively small number of patients could be included and the 6 month survival rates in the three prognostic groups (especially in the 'medium' and 'worse' groups) were generally higher than those obtained in the other analyses (Table V) . (6.7-12.2%) (2.8-8.0%) (4.1-12.1%) (0.5-3.3%) (2.4-5.5%) (5.3-12.6%) (4.9-6.9%) interval) Table IV Order of inclusion of the significant variables in the analyses
Results
n = 1,960 n = 1,631 n = 1,452 n = 1,364 n = 940 n = 674 n = 683 n = 520 n = 360 months PS*** PS*** PS*** PS*** PS*** PS*** PS*** Stage*** PS*** log AlkP*** log AlkP*** log AlkP*** log AlkP*** Stage*** log AlkP*** log AlkP*** PS*** log LDH*** Stage*** Stage*** Stage*** Stage*** log AST*** Stage*** Age*** Age* Age*** Stage*** Stage* Age*** log Na*** Age*** log Urea*** Age** Age** Age** log AlkP** Chloride* log Na*** log GGT** Albumin*** log Na*** log Na** log Na** log Na* log Na* Sex** log Na*** Sex* Sex* Age* More than n = 1,310 n = 1,119 n = 972 n = 916 n = 643 n = 480 n = 502 n = 392 n = 268 6 months Stage*** Stage*** Stage*** Stage*** Stage*** Stage*** Stage*** Stage*** Stage*** PS*** PS*** PS*** PS*** log Na*** PS*** PS*** Bicarb*** PS* log Na** log GGT*** log Na*** log AlkP** PS* log Na** log Na* PS** log AlkP** log Na* PS, performance status; AlkP, alkaline phosphatase; Na, sodium; GGT, gamma glutamyl transpeptidase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase. *P <0.05, **P<0.01, ***P<0.001. The reduced models consist of those variables above the horizontal lines. These results show that PS and disease stage are important prognostic factors in both periods. However, their relative importance changes over time with PS being paramount in the initial period and stage in the later period. The change in the relative importance of PS and stage and also of AlkP, Na and age can be illustrated by calculating the risk in the other category relative to that in the first (after categorising AlkP, Na and age) for the time periods 0-6 months, 6-24 months and more than two years after starting treatment (Table VII) . The primary importance of PS, AlkP and disease stage and the secondary role of Na and age in the first 6 months is shown by the high risk ratios. In the 6-24 month period, the risk ratios for AlkP, Na and age are close to unity indicating In all the analyses, PS and stage were both categorical variables, but AlkP was a continuous variable with a logtransformation (the respective coefficients were 0.735, 0.693 and 0.432). A complex equation of this form would be of little practical use for prognosis prediction in the clinical setting. Therefore, a simple index was devised with AlkP categorised into 'normal' (< 150 u 1-') and 'raised' (>150 u 1'). This index was used on the 1,995 patients for whom the values of all three variables were known. The outcomes of the index were divided into four groups and the 6 month and 2 year survival rates for these groups were calculated (Table VIII) ; the complete 2 year survival curves are shown in Figure 1 . The 6 month survival rates in groups 1 and 2 are similar, and they should perhaps be amalgamated. This gives three prognosis groups with six month survival rates of 81.4% (95% CI: 78.9-83.8%), 63.1% (59.4-66.8%) and 40.9% (35.9-46.0%) respectively (Table VIII) .
The initial exclusion of the MRC studies turned out to be fortuitous because it was possible to use two of them in a validation exercise of the prognostic index. As stated previously, certain variables were reported by some hospitals in the MRC studies but were not computerised. One of these was AlkP, which was reported for a high proportion of patients in the first two MRC studies (MRCI and MRC2). In addition, performance status in the form of an activity status score was available in the notes of almost all the patients in MRC1. These details were abstracted from the patients' notes and added to the computer file. The activity status scale used in MRC1 was not exactly the same as that in MRC2 (see Appendix), but it was possible to combine them so that they were compatible with the overall PS, as shown in Table IX . In these two data sets, there were 480 patients for whom PS, AlkP and disease stage were all known and Table X summarises some of the information about these patients.
Their median age was similar to those in the other six data sets (Table III) , although the proportion aged 65 years or more was rather low. The majority of patients in the first trial and all patients in the second had limited disease (LD).
The overall 2 year survival rate for these 480 patients was 7.1%, slightly better than the overall rate of the other six data sets (5.9%). The prognostic index was applied to these 480 patients (Table XI) PS, performance status; AlkP, alkaline phosphatase. *Prognosis groups I and 2 combined. 
Discussion
Although data on a total of 3,873 SCLC patients were received, it was only possible to use a maximum of 1,960 to identify the prognostic factors due to inconsistencies in the variables recorded and incomplete information. The individual studies were, of course, performed as independent research projects, not with the intention of using them in an overview analysis. The inconsistencies in the data sets meant that the overview had to be carried out as a series of analyses and, consequently, the results do not lead to such clear conclusions as might have been obtained if all variables had been measured in all the studies.
In this overview, a technique was employed in which patients were divided into three equal-sized groups, using the Cox scores calculated from the proportional hazards regression, and survival rates of the three groups calculated. An arbitrary range of ± 2.5% was used to decide whether the survival rates of three equal-sized groups determined by a subset of the prognostic factors were 'similar' to those obtained in the full model, i.e. that consisting of all significant factors in the analysis. This method was applied consistently in all the analyses.
There is, however, no generally accepted statistical method for constructing a prognostic index and other approaches could be used. Apart from the obvious constraint that the index must be reasonably simple to be of any clinical use, there are various statistical and practical questions which have to be answered somewhat arbitrarily.
1. Is the main aim to identify small subsets of patients with particularly good or bad prognosis? We could, for example, have divided the patients into the best 10%, the worst 10% and the remainder rather than into three equal-sized groups. and 2 combined.
PROGNOSTIC FACTORS IN SCLC 603
There were some important differences between the patients in the six data sets used to identify prognostic factors, especially in PS and disease stage ( In spite of these problems, the results of the analyses of the initial 6 month period indicate that PS, AlkP and disease stage are the most important prognostic factors (Table IV and V). In various subsets of the data, GGT, albumin, urea, AST, LDH and chloride were also significant variables, although after reduction only GGT, AST, LDH and chloride retained their importance in the relevant analyses. When models containing these variables were compared with one consisting of PS, AlkP and stage, a 'similar' degree of discrimination was obtained. It is possible that AST, LDH and, perhaps, GGT may be useful prognostic factors, which suggests that an adequate index is one consisting of PS, disease stage and a liver function test; the liver function test probably acts as an indicator of disseminated disease. AlkP, AST, GGT and LDH in the six data sets were not highly correlated, the strongest association being between AlkP and GGT (Spearman rank correlation coefficient = 0.49).
A simple prognostic index for the 6 months after starting treatment, based on the variables PS, AlkP and disease stage, was devised for the clinical setting. This index was shown to be effective, as one would expect, in the data from which it was developed, both as a whole and within each study, and was also validated in an independent data set. The survival rates of patients in the three prognosis groups in the MRC data were around 20% lower than the corresponding rates derived from the other studies. This difference may be related to the fact that both MRC studies were carried out some years ago. Consequently, it would be useful to test the index on a more recently collected cohort of SCLC patients. The simple index provides a degree of discrimination which is virtually identical to that provided by one incorporating the coefficients derived from the Cox model (Table XI) .
For those patients who survived the first 6 months, disease stage, PS and Na appear to be the important prognostic factors with stage being of primary importance. In addition, AlkP, GGT and bicarbonate were also significant variables in some of the analyses. Since the predictive power of most variables decreased with increasing duration of follow-up, a prognostic index for this later period based on the values of disease stage, PS and Na (or other variables) measured at the start of treatment is not particularly useful. A more relevant index for this period would be one derived from the values of PS, stage, Na, etc., measured in 6 month survivors, together with other variables such as response to treatment during the previous months and tumour progression. The decreasing predictive power of prognostic factors over time is also illustrated by the work of Souhami and Law (1990) . They analysed the survival of patients who were alive at 2 years in the studies included in this overview, together with 2 year survivors in some other SCLC studies. Disease stage and age did not have any predictive value for survival beyond 2 years.
The risk ratios for PS and stage for the patients who survived for 2 or more years appear to indicate that the patients with a PS score of 2 or 3 have a better prognosis than those with a score of 1 and that those with ED have a better prognosis than those with LD (Table VII) . This is, of course, most unlikely and is probably due to random variation. A surprisingly high proportion (39%) of the 104 two year survivors had a PS score of 2 or 3, while 19% were recorded as having ED; even higher proportions were found in some of the individual data sets. The different performance status scales used in the studies, which led to the derivation of an overall PS scale, may have reduced the prognostic efficiency of this variable. However, it is also likely that the high (and varying) proportions of 2 year survivors with a PS score of 2 or 3 and with ED indicate that standard criteria for these two variables may not have been applied in all hospitals.
There was certainly some variation in the evaluation of disease stage in the individual studies (Allan et al., 1984; Cerny et al., 1987; Cullen et al., 1986; MRC Lung Cancer Working Party, 1979 , 1981 , 1983 Smyth et al., 1986; Souhami et al., 1984 Souhami et al., , 1985 Vincent et al., 1987) . However, in general, the more complex tests and investigations, e.g. liver ultrasound scans, radioisotopic bone scans, bone marrow aspiration and CT scans, were only performed if there was clinical suspicion or 'plain' radiological evidence of extension beyond LD. Some of the investigations used to evaluate disease stage are time-consuming and unpleasant for the patient and, for this reason, Vincent et al. (1987) deliberately excluded stage from their attempt to devise a simple prognostic index. It should, nevertheless, be noted that there were important differences in survival between patients with LD and ED in their data. In an attempt to assess the value of disease stage, the nine analyses of the initial 6 month period (Tables IV and V) were re-performed omitting this variable. In the first analysis, it was found that a 'reduced' model consisting of PS and AlkP provided similar but not as good discrimination as that obtained with PS, AlkP and stage. However, unlike the original analyses which indicated quite consistently that PS, AlkP and stage were the most important variables, the results of the analyses omitting stage did not consistenly suggest a particular model that would act as a useful substitute. In all these analyses, the omission of stage reduced the degree of discrimination between the 'better' and 'medium' groups. Disease stage is the principal prognostic factor beyond 6 months and, therefore, this variable should not be omitted from any prognostic prediction for this period based on pretreatment measurements. Consequently, it is suggested that stage should continue to be assessed.
This overview has shown that, in the short-term (the 6 months after starting treatment), there are three groups of variables that are of importance for prognosis prediction. The first consists of PS, AlkP and disease stage which have been identified as being of primary importance. The second group comprises age, sex, Na, GGT, albumin, urea and chloride; these variables significantly improved the goodness of fit in the proportional hazards regression analyses, but the improvement in the prediction of survival obtained by their inclusion was small. LDH and AST form the third group; they are potentially important prognostic factors, but the relatively small numbers of patients for whom these measurements were available prevented any definitive conclusions about their role. In the longer term (6-24 months), stage, PS and Na are the significant variables, although stage appears to be the most important.
These results, therefore, led the Subcommittee to recommend that in future SCLC studies, performance status, disease stage, AlkP, Na, AST and LDH should be recorded; in addition, it is preferable that GGT, albumin, urea, plasma chloride and blood bicarbonate should also be measured. It should be stressed, however, that standard criteria must be applied meticulously when determing performance status and disease stage. The recording of the recommended measurements would allow standardised comparisons between new studies and possibly the selection of patients for different treatment strategies. It would also facilitate another overview of SCLC studies at some future date which should validate the present analysis and lead to more definite conclusions about prognostic factors for this disease.
